With the discovery of ferroptosis regulatory factors in cancer and chemotherapy drug resistance targets, such as transmembrane protein 160 (TMEM160) [127], syntaxin 1A (STX1A) [128], vimentin-Interacting protein AS39 (VIPAS39) [129], and serine/threonine-protein kinase (SIK1) [130], the expansion of the target range has also broadened the application of combined treatment. This evidence concerns the gene TMEM160 and cancer.